Antiplatelet up-and-comers: heartwire collection

Editorial series

Antithrombotic therapies in ACS: An update from Europe

Jan 30, 2012 10:30 EST

Drs Jean-Pierre Bassand, Peter Clemmensen, and Jean-Philippe Collet review the latest data on antithrombotic therapies in ACS. Hear the European perspective on antiplatelet therapy, anticoagulation agents, and anticoagulants in the setting of primary PCI.

The Cardiology Show

AHA 2011 trials to treatments: ATLAS ACS2, TRACER, and MI FREEE

3 COMMENTS - Nov 16, 2011 14:30 EST

Dr Valentin Fuster sits down with Drs William Boden, John Chapman, Keith Fox, Anne Gillis, Jessica Mega, and Clyde Yancy to tackle the brave new world of antithrombotics and to ask whether academics have left the real world, and their patients, behind.

Editorial series

Novel anticoagulants in AF: A guide for the clinical practitioner

2 COMMENTS - Sep 15, 2011 10:47 EDT

Join Drs Samuel Goldhaber, Jean-Pierre Bassand, Stavros Konstantinides, and Alexander GG Turpie as they guide the clinical practitioner through the landscape of novel anticoagulants in AF.

Editorial series

Antiplatelet guidelines: An international perspective

Jun 10, 2011 09:00 EDT

Dr Bob Harrington sits down with Drs Alan Bell, Keith Fox, and Jean-François Tanguay for an in-depth discussion on the approach, development, methodology, and implementation of guidelines for antiplatelet therapy in Canada, the US, and Europe.

Editorial series

Dual antiplatelet therapy: How long is long enough?

3 COMMENTS - Jun 2, 2011 10:30 EDT

Join Drs David Kandzari, Bob Harrington, and Laura Mauri as they discuss the results of EXCELLENT and why we may need to change the way we do clinical trials to answer the real questions about dual antiplatelet therapy.

Acute Coronary Syndromes

Ticagrelor approved in Canada

Jun 1, 2011 13:15 EDT

Health Canada has granted approval to ticagrelor for the secondary prevention of atherothrombotic events in patients with ACS. The FDA has twice postponed a decision on the drug.

Acute Coronary Syndromes

Debate continues on ticagrelor in PLATO

3 COMMENTS - Mar 11, 2011 15:30 EST

UPDATED // Just why ticagrelor did not show a mortality benefit over clopidogrel in the US and Canadian patients in the pivotal PLATO trial—believed to be one of the main reasons the FDA has yet to approve this drug—is once again thrashed out in a newly published viewpoint and two accompanying editorials.

Acute Coronary Syndromes

Prasugrel preferable to high-dose clopidogrel in diabetics?

Jan 26, 2011 10:00 EST

Further evidence supporting the concept that prasugrel may be a more appropriate antiplatelet agent than even high-dose clopidogrel for diabetic patients has come from a new platelet-function study.

Interventional/Surgery

PLATO CABG published, but mortality, bleeding analyses with ticagrelor continue

1 COMMENT - Dec 29, 2010 16:00 EST

The analysis of patients in PLATO who subsequently underwent CABG has been published, but the investigators admit they still have not managed to nail down exactly why mortality differed between the ticagrelor and clopidogrel groups, while bleeding did not. They are continuing to drill down into the data, looking at exact causes of death, and hope to have more answers on the subject in 2011.

Acute Coronary Syndromes

No US approval for ticagrelor yet; FDA requests further analysis of PLATO

6 COMMENTS - Dec 17, 2010 12:15 EST

The FDA has once again delayed a decision on the US approval of AstraZeneca's new antiplatelet drug ticagrelor, requesting additional analyses of the PLATO trial. One expert says there is much to resolve.

Acute Coronary Syndromes

Ticagrelor approved in Europe for ACS patients

2 COMMENTS - Dec 6, 2010 15:30 EST

The European Medicines Agency approved ticagrelor in combination with aspirin for prevention of atherothrombotic events after an MI or episode of unstable angina.

Editorial series

AHA 2010 research highlights: A slideshow presentation

2 COMMENTS - Nov 23, 2010 14:55 EST

Read our slideshow for an overview of top research from AHA 2010 with the latest from ADVANCE, RAFT, EMPHASIS, ASCEND HF, ROCKET AF, CLOSURE I, GRAVITAS, P-OM3, PROTECT-AF, BASKET PROVE, DEFINE, SYMPLICITY HTN, ASCOT CRP, and ACT.

The Cardiology Show

ROCKET AF, EMPHASIS-HF, and DEFINE: AHA 2010 Overview from Chicago

4 COMMENTS - Nov 17, 2010 16:00 EST

Dr Valentin Fuster sits down with Drs C Noel Bairey Merz, Roger Blumenthal, Sunil Rao, Renu Virmani, Lars Wallentin, and James Young for an in-depth discussion on the important trials presented at the AHA 2010 Scientific Sessions.

Thrombosis

New pharmacodynamic data confirm PLATO genetics substudy findings

Nov 15, 2010 16:45 EST

The first comparative clinical study of CYP2C19 genotype on ticagrelor pharmacodynamics shows that the new investigational antiplatelet agent is better at inhibiting platelet function than clopidogrel, irrespective of genotype or metabolizer status. The findings confirm the previous results of the PLATO pharmacogenetics substudy, say the researchers.

Acute Coronary Syndromes

First of their kind: Canadian guidelines specific to antiplatelet therapy

7 COMMENTS - Oct 29, 2010 16:00 EDT

The new guidelines include recommendations on dual antiplatelet therapy duration and the role of prasugrel and COX 2 inhibitors and, for the first time, recommend against the routine use of aspirin for primary prevention.

Interventional/Surgery

Atopaxar passes early test in LANCELOT-ACS: No bleeding risk compared with placebo

Sep 27, 2010 16:30 EDT

In addition to no significant increases in bleeding with the investigational agent, investigators say atopaxar was well tolerated, achieved rapid platelet inhibition, and resulted in a significant reduction in Holter-detected ischemia.

Acute Coronary Syndromes

Europe's CHMP backs ticagrelor for approval in ACS

Sep 24, 2010 13:45 EDT

It's now up to the European Commission to decide whether to grant approval for the clopidogrel competitor.

Acute Coronary Syndromes

Switching from clopidogrel to prasugrel further reduces platelet function

Sep 20, 2010 11:30 EDT

Switching from maintenance clopidogrel to prasugrel results in a further reduction in platelet function after one week, according to a new study. When patients receive a loading dose of prasugrel prior to switching from maintenance clopidogrel, the reduction in platelet function occurs within two hours, report investigators.

Interventional/Surgery

First "comparison" of prasugrel and ticagrelor

3 COMMENTS - Sep 16, 2010 17:30 EDT

A new "indirect comparative meta-analysis" of prasugrel and ticagrelor in ACS patients has suggested that prasugrel may be associated with fewer stent thromboses, whereas ticagrelor causes fewer bleeding complications.

Editorial series

CURRENT-OASIS 7, CURE, ACTIVE A, and INNOVATE PCI: Exploring the world of antiplatelet therapy

1 COMMENT - Sep 15, 2010 15:30 EDT

Dr Keith Fox sits down with Dr Harvey White at the ESC 2010 Congress to discuss whether antiplatelet therapy is getting simpler or more complicated in light of new data presented.

Acute Coronary Syndromes

New class of antiplatelet agents in clinical trials

Aug 30, 2010 11:30 EDT

A new, investigational antiplatelet agent, atopaxar—which acts via a different pathway from that of aspirin and drugs such as clopidogrel and ticagrelor—has shown promising results in a phase 2 trial. Another agent from the same class, vorapaxar, is already in phase 3 trials.

Acute Coronary Syndromes

INNOVATE PCI: Elinogrel, a new antiplatelet agent, passes initial hurdles

Aug 30, 2010 09:30 EDT

Investigators showed that treatment with oral and intravenous elinogrel had more rapid antiplatelet effects than clopidogrel in the acute and chronic phases of therapy. Although still in early days, the hope is that reversible platelet inhibition may mitigate some of the bleeding risks and improve clinical outcomes.

Acute Coronary Syndromes

New PLATO data: No need for gene testing in PCI patients

1 COMMENT - Aug 29, 2010 13:00 EDT

New data from genetic substudies of PLATO and TRITON-TIMI 38 show that the efficacy of the new antiplatelet agents ticagrelor and prasugrel do not seem to be affected by loss-of-function genetic variants that contribute in some instances to worse outcomes in those on clopidogrel. Using these new agents means that routine testing for clopidogrel genetic variation is not necessary, say the authors and others; the new drugs should be used when possible in patients with a medium to high risk of thrombotic complications after stenting.

Acute Coronary Syndromes

Advisory panel votes to recommend FDA approval of ticagrelor

5 COMMENTS - Jul 28, 2010 17:20 EDT

UPDATED // An FDA advisory panel voted overwhelmingly in favor of approval of AstraZeneca's antiplatelet agent Brilinta for preventing thrombotic events in patients with ACS

Acute Coronary Syndromes

FDA advisors to contemplate PLATO at July 28 meeting on ticagrelor

Jul 26, 2010 15:00 EDT

FDA's Cardiovascular and Renal Drugs Advisory Committee will review AstraZeneca's new drug application for ticagrelor, the proposed new antiplatelet drug for patients with acute coronary syndrome.